Financial Performance - Total revenue for the fiscal year ending December 31, 2025, was HKD 467,457,000, an increase of 28.7% from HKD 363,350,000 in the previous year[3] - Commission and fee income reached HKD 319,934,000, up 46.9% from HKD 217,674,000 year-over-year[3] - Net interest income increased to HKD 62,329,000, compared to HKD 53,004,000 in the previous year, reflecting a growth of 17.4%[3] - The company reported a profit before tax of HKD 183,745,000, significantly higher than HKD 68,102,000 in the previous year, marking an increase of 170.5%[3] - The net profit for the year was HKD 151,225,000, compared to HKD 50,792,000 in the previous year, representing a growth of 197.5%[4] - Basic and diluted earnings per share were both HKD 13.77, compared to HKD 4.59 in the previous year, indicating a substantial increase[3] - Total comprehensive income for the year amounted to HKD 239,724,000, up from HKD 138,719,000 in the previous year, reflecting a growth of 72.6%[4] Asset and Liability Management - Non-current assets increased to HKD 40,676 million from HKD 70,434 million year-over-year, reflecting a decrease of approximately 42.4%[5] - Current assets reported at HKD 1,548,748 million, showing a slight increase from HKD 1,539,976 million, representing a growth of about 0.5%[5] - Accounts receivable rose to HKD 1,420,258 million, up from HKD 778,325 million, indicating an increase of approximately 82.5%[5] - Cash and cash equivalents reached HKD 742,820 million, compared to HKD 248,550 million, marking a significant increase of about 198.5%[5] - The company reported total assets of HKD 5,484,496 million, up from HKD 3,774,063 million, reflecting an increase of approximately 45.3%[5] - The company’s liabilities decreased to HKD 1,420,258 million from HKD 778,325 million, indicating a reduction of approximately 82.5%[5] - The company’s total equity increased significantly, reflecting strong financial health and growth potential[5] Future Outlook and Strategy - The company is focusing on expanding its market presence and investing in new technologies to drive future growth[5] - Future guidance indicates a positive outlook with expected revenue growth driven by new product launches and market expansion strategies[5] - The company plans to expand its asset management services and enhance its financing offerings to drive future growth[18] Revenue Sources - Customer contract revenue for 2025 reached HKD 319,934 thousand, a significant increase from HKD 217,674 thousand in 2024, representing a growth of approximately 47%[18] - Commission income from brokerage and related services was HKD 17,617 thousand in 2025, up from HKD 8,401 thousand in 2024, marking a growth of 109%[15] - Income from asset management services increased to HKD 166,244 thousand in 2025, compared to HKD 135,944 thousand in 2024, reflecting a growth of 23%[18] - Interest income from providing financing and securities collateral financing was HKD 30,532 thousand in 2025, compared to HKD 9,219 thousand in 2024, indicating a growth of 231%[16] - Total income from other sources reached HKD 467,457 thousand in 2025, up from HKD 363,350 thousand in 2024, representing a growth of 29%[18] Impairment and Credit Losses - The company reported a decrease in impairment losses to HKD (4,960,000) from HKD (18,189,000), indicating improved asset quality[3] - The impairment loss recognized for the year was HKD 4,331,000 in 2025, compared to HKD 3,087,000 in 2024, marking an increase of approximately 40.3%[33] - The estimated impairment loss provision for the year ending December 31, 2025, is HKD 49,155,000, compared to HKD 1,424,000 in 2024, indicating a substantial increase in expected credit losses[40] Risk Management - The company has established a Risk Management and Internal Control Committee to oversee its risk management framework[117] - The company has implemented comprehensive risk management policies and internal control procedures to monitor and manage various business risks[117] - The company emphasizes compliance training to enhance the awareness of compliance among all employees, especially front-line business personnel[3] Shareholder Returns - The company did not declare or pay any dividends for the years ending December 31, 2025, and December 31, 2024[31] - The company repurchased a total of 2,287,000 shares during the reporting year, with a total cost of approximately HKD 652,000[122] Employee and Administrative Costs - Employee costs, including salaries and wages, amounted to HKD 85,264,000 in 2025, compared to HKD 98,235,000 in 2024, reflecting a decrease of approximately 13.2%[26] - The total employee cost for the reporting year was approximately HKD 99.9 million, compared to HKD 86.7 million in the previous year[111] Compliance and Governance - The company has adhered to all applicable corporate governance rules throughout the reporting year[118] - The Audit Committee reviews the consolidated financial statements and internal audit reports to ensure compliance with internal control policies[81]

Financial Performance - The total revenue for the year ending December 31, 2025, is reported at HKD 1,341,205,000, representing an increase of 6.2% from HKD 1,263,129,000 in 2024[3] - Gross profit for the same period is HKD 453,926,000, down 12% from HKD 515,149,000 in 2024[3] - Net profit for the year is HKD 126,040,000, which is a significant increase of 86% compared to HKD 67,633,000 in 2024[3] - The cost of sales increased to HKD 887,279,000, up from HKD 747,980,000 in the previous year, indicating a rise of 18.6%[3] - Administrative expenses rose to HKD 273,843,000, compared to HKD 256,649,000 in 2024, reflecting a growth of 6.7%[3] - Total comprehensive income for the year amounted to HKD 85,412,000, compared to HKD 114,654,000 in the previous year, representing a decrease of approximately 25.5%[4] - Basic earnings per share for the year was HKD 8, a decrease from HKD 14.29 in the previous year, reflecting a decline of about 44.9%[4] - The total tax expense for the year is HKD 26,787,000 for 2025, compared to HKD 36,070,000 for 2024, representing a decrease of approximately 25.5%[29] Assets and Liabilities - Non-current assets increased to HKD 395,656,000 in 2025 from HKD 373,487,000 in 2024, indicating a growth of approximately 5.9%[5] - Current assets rose to HKD 626,207,000 in 2025, up from HKD 582,125,000 in 2024, marking an increase of about 7.6%[5] - The company’s total liabilities increased to HKD 626,207,000 in 2025, compared to HKD 582,125,000 in 2024, indicating an increase of about 7.6%[5] - As of December 31, 2025, total current liabilities amounted to HKD 328,790,000, an increase from HKD 239,851,000 as of December 31, 2024, representing a growth of approximately 37.1%[6] - The company's total equity as of December 31, 2025, was HKD 619,336,000, down from HKD 654,102,000, reflecting a decrease of approximately 5.3%[6] - The company’s cash and cash equivalents decreased to HKD 187,474,000 in 2025 from HKD 267,235,000 in 2024, a decline of approximately 30%[5] Market and Strategic Initiatives - The company has plans for market expansion and new product development, although specific details were not disclosed in the earnings report[2] - Future guidance indicates a focus on increasing revenue through strategic partnerships and technological advancements[2] - The company plans to continue its market expansion and product development strategies in the upcoming fiscal year[4] - The company is considering the application of IFRS 19 for certain specific financial statements of its subsidiaries[14] - The company plans to expand into emerging markets such as the Middle East, Africa, and Southeast Asia, focusing on high-growth sectors like new energy and green economy[46] Governance and Compliance - The company is controlled by Mr. Li Xiangli and Ms. Zhang Aiying, who are spouses, indicating a familial governance structure[8] - The company has adopted the Corporate Governance Code and believes it has complied with its provisions, except for a deviation regarding the roles of the chairman and CEO[81][82] - The company has established an Audit Committee in accordance with the Listing Rules, consisting of three independent non-executive directors[85] - Ernst & Young has confirmed that the financial figures in the preliminary announcement are consistent with the group's financial statements for the year[86] Research and Development - Research and development costs for the year are approximately HKD 30,451,000 for 2025, slightly down from HKD 30,657,000 in 2024[30] - The group is focusing on AI as a key technology application, making significant strategic investments in AI and robotics to enhance business processes towards automation and intelligence[42] - The group will focus on increasing R&D resource investment, particularly in AI technology and its integration with testing services, targeting key technologies like intelligent carbon emission calculation models by 2026[57] Employee and Workforce - The group expanded its workforce by adding 218 overseas employees, bringing the total global workforce to 3,408, with 82 global branches and professional laboratories covering over 20 countries[41] - As of December 31, 2025, the group has a total of 3,408 employees, an increase from 3,374 in 2024[72] Carbon Market and ESG Initiatives - The group has been recognized as one of the most important carbon asset traders in the Beijing carbon market, with a continuous expansion in carbon asset trading scale, helping more clients achieve annual compliance at lower costs[52] - The group received the "Best Trading Award for 2024" from the Beijing Green Exchange, reflecting its strong practical experience and brand credibility in the carbon market[52] - The group is committed to advancing its ESG strategy, focusing on green low-carbon and sustainable growth potential markets, while actively exploring potential acquisition targets and investment opportunities[56] Financial Reporting Standards - The company has adopted the revised International Financial Reporting Standards, specifically IAS 21, which assesses currency convertibility, but it did not impact the financial statements due to the nature of the currencies used in transactions[9] - The company is currently analyzing the impact of IFRS 18 on its financial statement presentation and disclosures[12] - The amendments to IFRS 9 and IFRS 7 are not expected to have a significant impact on the company's financial statements[15]

MIKO INTERNATIONAL HOLDINGS LIMITED 米格國際控股有限公司 （於開曼群島註冊成立的有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責， 對其準確性或完整性亦不發表聲明，並表明概不就因本公佈全部或任何部分內容 所導致或因倚賴該等內容而產生的任何損失承擔任何責任。 （股份代號：1247） 截至2025年12月31日止年度的年度業績公佈 米格國際控股有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈本公司及其 附屬公司（統稱「本集團」）截至2025年12月31日止財政年度（「2025年財政年度」）的 經審核綜合業績，連同截至2024年12月31日止年度（「2024年財政年度」）的比較數 字。該等業績乃根據國際財務報告準則（「國際財務報告準則」）編製，並已由本公 司審核委員會審閱如下。 1 綜合損益及其他全面收益表 截至2025年12月31日止年度（以人民幣列示） | | | 2025年 | 2024年 | | --- | --- | --- | --- | | | 附註 | 人民幣千元 | 人民幣千元 | | 收益 | 3 | 608,415 ...

Financial Performance - Total revenue for the year 2025 was RMB 2,070,984, a decrease of 54.6% compared to RMB 4,565,434 in 2024[3] - The normalized net loss for 2025 was RMB (47,571), a reduction of 62.6% from RMB (127,076) in 2024[4] - The gross profit margin improved to 15.0% in 2025 from 8.5% in 2024, despite total gross profit declining to RMB 311,325, a 19.4% decrease[3] - The company incurred a net loss of RMB 126,778 thousand for the year, significantly improved from a loss of RMB 361,832 thousand in 2024[57] - The company's loss before tax for 2025 was RMB 128,156,000, a decrease from RMB 360,641,000 in 2024, indicating a significant improvement in financial performance[87] Revenue Breakdown - The business insurance services segment generated revenue of RMB 141,579, down 26.6% from RMB 192,958 in 2024, with corporate insurance increasing by 32.0% to RMB 90,711[3] - Revenue from the commercial insurance services business decreased by 26.6% to approximately RMB 141.6 million in 2025, primarily due to the restructuring of the Huiminbao business segment[27] - Revenue from the doctor research assistance business increased by 16.3% to approximately RMB 462.3 million in 2025, driven by growing market demand[28] - Revenue from the specialty pharmacy business fell by 63.1% to approximately RMB 1.47 billion in 2025, mainly due to strategic restructuring[29] Operational Highlights - The company's enterprise insurance services achieved a managed premium of RMB 1.09 billion, a year-on-year increase of 47.8%[16] - The number of serviced enterprises reached 619, reflecting a year-on-year growth of approximately 30.0%[16] - Total membership served surpassed 2.04 million, marking a year-on-year increase of about 79.2%[16] - The company established partnerships with nearly 100 domestic leading insurance companies and signed a five-year strategic cooperation agreement with Gallagher for customized insurance solutions[17] - The company operates 70 corporate clinics, with nearly 200,000 patient visits in 2025, up from approximately 120,000 in 2024[18] Strategic Initiatives - The company aims to enhance its core capabilities in insurance brokerage services and improve service quality and scale[9] - The strategic focus includes optimizing the structure of specialty pharmacy and health insurance services to improve overall gross margin and operational efficiency[10] - The company plans to expand its service offerings in property insurance, life sciences insurance, and reinsurance to meet the growing comprehensive risk management needs of enterprises[10] - Future strategies include leveraging global best practices in insurance brokerage to become a leading comprehensive risk management expert in China[11] - The group has established three new departments: Reinsurance, Large Commercial Risks, and Life Sciences Insurance, to enhance service capabilities and risk management solutions[23] Financial Position - Cash and specific financial assets decreased by 21.8% to RMB 931,750 from RMB 1,191,944 in 2024[4] - As of December 31, 2025, the company recorded a net current asset value of approximately RMB 572.3 million, with a debt-to-asset ratio of about 43.9%, down from 47.0% in 2024[42] - The company has no outstanding bank loans or other borrowings as of December 31, 2025, and expects future cash flow from commercialized product sales[42] - Total non-current assets increased to RMB 340,345,000 in 2025 from RMB 285,165,000 in 2024, representing an increase of approximately 19.4%[59] - Current assets decreased to RMB 1,262,563,000 in 2025 from RMB 1,980,127,000 in 2024, a decline of about 36.2%[59] Cost Management - Total sales costs decreased by 57.9% to approximately RMB 1.76 billion in 2025, consistent with the revenue decline, primarily due to the strategic restructuring of the specialty pharmacy and Huiminbao business segments[30] - Sales and marketing expenses decreased by approximately 53.7% from about RMB 278.4 million in 2024 to about RMB 128.8 million in 2025, attributed to efficiency improvements in the commercial insurance services business and strategic restructuring in other segments[33] - Administrative expenses decreased by approximately 17.9% from about RMB 324.0 million in 2024 to about RMB 265.9 million in 2025, mainly due to organizational optimization and increased administrative efficiency through digitization[34] - Research and development expenses decreased by approximately 54.2% from about RMB 22.3 million in 2024 to about RMB 10.2 million in 2025, primarily due to strategic restructuring in specific business segments[35] Shareholder Information - The company has no controlling shareholder, indicating a diversified ownership structure[62] - The company did not declare or pay any dividends during the year, consistent with 2024[88] - The board did not recommend the payment of a final dividend for the year ended December 31, 2025[55] - The company has not adopted a dividend policy and plans to retain most of its available funds for business development and growth[101] Corporate Governance - The company aims to maintain high standards of corporate governance and has adopted the corporate governance code as per the Stock Exchange listing rules[99] - The board believes that the current structure, with the same individual serving as both Chairman and CEO, ensures consistent leadership and effective strategic planning[100] - The company plans to review its corporate governance practices regularly to ensure compliance and effectiveness[99] - The audit committee, along with the board and external auditors, reviewed the accounting standards and practices adopted by the group for the fiscal year ending December 31, 2025[104]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 China Tourism Group Duty Free Corporation Limited 中國旅遊集團中免股份有限公司 （一家於中華人民共和國註冊成立的股份有限公司） （股份代號：1880） 截至2025年12月31日止年度業績公告 中國旅遊集團中免股份有限公司（「本公司」）董事會（「董事會」）欣然宣佈本公司 及其附屬公司（「本集團」）截至2025年12月31日止年度之經審核年度業績。本公 告載列本公司2025年年度報告（「年度報告」）全文，並符合香港聯合交易所有限公 司證券上市規則中有關年度業績初步公告附載資料之要求。 本集團截至2025年12月31日止年度之年度業績已由董事會審計與風險管理委員會 審閱。 本公告將於香港交易及結算所有限公司（「香港交易所」）網站( www.hkexnews.hk ) 及本公司網站( www.ctgdutyfree.com.cn )刊載。年度報告將於適當時候於 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607) 2025年度業績公告 上海醫藥集團股份有限公司（「本公司」）董事會（「董事會」）欣然發佈本公司及其附屬公司 （合稱「本集團」）截至2025年12月31日之年度業績。該年度業績乃根據中國企業會計準則 編製，並經德勤華永會計師事務所（特殊普通合夥）審核。董事會審計委員會已審閱此年 度業績。 本公司2025年度報告的全部內容附於本公告後。正式年度報告將於適當時候在香港聯合 交易所有限公司的網站(www.hkexnews.hk)和本公司網站(www.sphchina.com)刊登。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，二零二六年三月三十一日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先 ...

[ Stock Code: 00525 ] 廣 深 鐵 路 2025 年 年 度 報 告 001 重要提示 公司第十屆董事會第二十次會議已於2026年3月30日審議通過了報告期利潤分配預案（現金分紅方案），董事 會建議公司2025年年度以實施權益分派股權登記日登記的總股本為基數分配利潤，向全體股東每股派發現金 股息人民幣0.09元（含稅），按截止2025年12月31日公司總股本7,083,537,000股計算，合計派發現金股息人 民幣637,518,330元（含稅），如在實施權益分派的股權登記日前公司總股本發生變動，公司將維持分配總額 不變，相應調整每股分配金額。該預案尚需提呈公司2025年年度股東會審議批准後方可實施。 六、 前瞻性陳述的風險聲明 ✓適用 □不適用 本年度報告中如有涉及未來計劃、發展戰略等前瞻性描述，不構成公司對投資者的實質承諾，投資者及相關 人士均應當對此保持足夠的風險認識，並且應當理解計劃、預測與承諾之間的差異。 七、 是否存在被控股股東及其他關聯方非經營性佔用資金情況 否 八、 是否存在違反規定決策程序對外提供擔保的情況 否 九、 是否存在半數以上董事無法保證公司所披露年度報告的真實性 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而 產生或因依賴該等內容而引致的任何損失承擔任何責任。 GOLDEN WHEEL TIANDI HOLDINGS COMPANY LIMITED 金輪天地控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1232） 金輪天地控股有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈，本公司及其附 屬公司（統稱「本集團」）截至二零二五年十二月三十一日止年度的經審核年度綜合業績， 連同上一年度的比較數字。 綜合損益表 （以人民幣列示） | | | 二零二五年 | 二零二四年 | | --- | --- | --- | --- | | | 附註 | 人民幣千元 | 人民幣千元 | | 收益 | 3 | 452,684 | 796,376 | | 銷售成本 | | (412,866) | (823,758) | | 毛利╱（損） | | 39,818 | (27,382) | | 投資物業公平值變動 | | (282,456) | (468,186) ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 2025年年度業績公告 廣深鐵路股份有限公司（「本公司」）董事會（「董事會」）欣然宣佈本公司及其附屬 公司截至2025年12月31日止年度的經審核業績。本公告列載本公司2025年年度報告全文， 並符合香港聯合交易所有限公司（「香港聯交所」）證券上市規則中有關年度業績初步 公告附載資料的要求。 本業績公告和本公司2025年年度報告的中英文版本可在本公司網站(www.gsrc.com)和香港 聯交所披露易網站(www.hkexnews.hk)查閱。 承董事會命 廣深鐵路股份有限公司 蔣輝 董事長 中國•深圳 2026年3月30日 於本公告發出之日，董事會成員包括： 執行董事 非執行董事 蔣輝 鐘寧 湯小凡 陳少宏 李丹江 邱自龍 周尚德 劉啟義（職工代表董事） 王琴 獨立非執行董事 廣 深 鐵 路 2025 年 年 度 報 告 001 重要提示 公司第十屆董事會第二十次會議已於2026年3月30日審議通過了 ...

Financial Performance - Total revenue for the year ending December 31, 2025, was CNY 1,191,439,000, an increase from CNY 1,119,646,000 in the previous year, representing a growth of approximately 6.4%[2] - Cost of sales for the same period was CNY 1,172,170,000, compared to CNY 1,106,868,000 in the prior year, indicating an increase of about 5.9%[2] - Gross profit amounted to CNY 19,269,000, up from CNY 12,778,000, reflecting a significant increase of approximately 50.9%[2] - Operating loss for the year was CNY 12,815,000, compared to a loss of CNY 11,831,000 in the previous year, showing a deterioration in performance[2] - Net loss for the year was CNY 10,477,000, compared to a loss of CNY 8,842,000 in the prior year, indicating an increase in losses of about 18.5%[2] - Basic and diluted loss per share was CNY 1.1, compared to CNY 1.0 in the previous year, reflecting a slight increase in loss per share[2] Revenue Breakdown - Revenue from refined oil sales was RMB 738,207,000 for 2025, down from RMB 1,013,353,000 in 2024, indicating a decline of about 27.2%[18] - Revenue from other petrochemical products increased significantly to RMB 398,373,000 in 2025, compared to RMB 80,465,000 in 2024, reflecting a growth of approximately 394.5%[18] - Service income for the fiscal year was RMB 11,368,000, a decrease from RMB 25,828,000 in the previous year, showing a decline of about 56.0%[18] - External customer transactions accounted for approximately 10% of total revenue, with significant contributions from major clients, including RMB 430,758,000 from Client A and RMB 548,488,000 from Client B[19] Assets and Liabilities - Total assets increased to RMB 783.68 billion, up from RMB 463.06 billion[3] - Current assets rose significantly to RMB 765.32 billion compared to RMB 437.95 billion[3] - Total liabilities reached RMB 371.50 billion, an increase from RMB 40.40 billion[3] - The company reported a total equity of RMB 412.18 billion, slightly down from RMB 422.66 billion[3] - Cash and cash equivalents amounted to RMB 31.94 billion, compared to RMB 33.41 billion[3] - The company has a total of RMB 97.37 billion in retained earnings, down from RMB 107.76 billion[3] Taxation and Financial Income - The company reported a tax benefit of CNY 2,970,000, compared to CNY 1,758,000 in the previous year, indicating an increase of about 68.8%[2] - The company has been exempt from paying profits tax in Hong Kong due to its registration as an exempt limited company in the Cayman Islands, with no taxable profits reported for the year ending December 31, 2025[23] - The standard corporate income tax rate for the company's entities in China is 25%, consistent with the previous year[24] - Financial income for the year was CNY 2,557,000, up from CNY 1,406,000, representing an increase of approximately 81.8%[2] Strategic Initiatives - The company is focusing on expanding its market presence and developing new products and technologies to drive future growth[2] - Strategic initiatives include potential mergers and acquisitions to enhance competitive positioning in the market[2] Employee and Governance - The total employee cost for the group is approximately RMB 6,251,000, compared to RMB 6,166,000 in 2024[67] - The group has 18 full-time employees in China and Hong Kong as of December 31, 2025[67] - The company emphasizes the importance of employees as valuable assets and conducts annual performance reviews to determine salary adjustments and promotions[67] - The company has adhered to the corporate governance guidelines as per the listing rules up to December 31, 2025[77] - All directors confirmed compliance with the trading standards as of December 31, 2025[78] - The audit committee is responsible for reviewing and supervising the financial reporting process and internal control systems[79] Cash Flow and Investments - The net cash generated from operating activities for the year ending December 31, 2025, was approximately RMB 300,960,000, attributed to an increase in operating working capital[51] - The net cash used in investing activities for the year ending December 31, 2025, was approximately RMB 301,633,000, primarily due to deposits for pledged deposits[52] - The group has not made any significant investments or major acquisitions or disposals of subsidiaries and associates as of December 31, 2025[56] Compliance and Risk Management - The group has no significant violations or non-compliance with applicable laws and regulations that would have a material impact on its business and operations[66] - The board believes that the foreign exchange rate risk is not significant, and therefore no financial instruments are used to hedge this risk[65] Dividends and Shareholder Information - No dividends were paid or payable for the year ending December 31, 2025, consistent with the previous year[29] - The annual report containing all required information will be sent to shareholders and published on the stock exchange and the company's website[81]